BioCorRx Inc. (OTC: BICX) announced the appointment of Richard J. Baum to its Strategic Advisory Board, bringing nearly three decades of federal drug policy experience to the addiction treatment company. Baum served as Acting Director of the White House Office of National Drug Control Policy (ONDCP) and Executive Director of the President's Commission on Combating Drug Addiction and the Opioid Crisis. His addition signals BioCorRx's intent to deepen its engagement with policymakers and public health agencies as it advances both treatment programs and pharmaceutical candidates.
Baum's 28 years at ONDCP spanned six presidential administrations, where he helped shape federal responses to evolving drug threats, including the opioid crisis. His expertise covers treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners. BioCorRx expects to leverage that systems-level knowledge as it promotes LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication for mitigating opioid withdrawal symptoms, and BICX104, its investigational biodegradable naltrexone implant technology. The company also operates treatment support programs such as Beat Addiction Recovery and UnCraveRx®, a medication-assisted weight loss program that includes access to concierge wellness specialists. For more information on UnCraveRx®, visit www.uncraverx.com.
"Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx," said Lourdes Felix, CEO of BioCorRx Inc. "His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care." The appointment comes as the nation continues to confront high rates of opioid use disorder and methamphetamine use. According to the 2025 National Survey on Drug Use and Health, approximately 4.0 million people in the United States aged 12 or older had an opioid use disorder in the past year, while about 2.7 million reported using methamphetamine in the past year.
Baum also highlighted the company's research into BICX104 as a potential treatment for methamphetamine use disorder. "In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company's research evaluating BICX104, an investigational long-duration naltrexone implantable pellet," Baum said. The ongoing clinical study of BICX104 is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. BioCorRx Pharmaceuticals Inc., a subsidiary, focuses on pharmaceutical commercialization and development. More details are available at www.BioCorRx.com.
Baum's credentials include serving as an Adjunct Professor at Georgetown University's McCourt School of Public Policy and authoring Inside America's Opioid Crisis: 12 Hard Lessons for Today's Drug War. He is also on the United Against Fentanyl Board of Directors. His appointment could help BioCorRx navigate the complex policy landscape surrounding addiction treatment, where access to evidence-based care remains a critical challenge. By adding a figure with deep federal experience, the company aims to bolster its credibility and strategic positioning as it seeks to expand treatment options for substance use disorders.
